SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma

• Main Authors: Ampudia-Mesias, E. (Author), Cameron, C.S (Author), El-Hadad, S. (Author), Saydam, N. (Author), Saydam, O. (Author), Ströbel, T. (Author), Wöhrer, A. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: EVs; glioblastoma; proteomics; SRPX
• Online Access: View Fulltext in Publisher

 Extracellular vesicles (EVs) may be used as a non-invasive screening platform to discover markers associated with early diagnosis, prognosis, and treatment response. Such an approach is invaluable for diseases such as glioblastoma, for which only a few non-invasive diagnostic or prognostic markers are available. We used mass spectrometry to analyze proteomics profiles of EVs derived from four glioblastoma cell lines and human primary astrocytes (HPAs) and found that SRPX is the only protein enriched in the majority of glioblastoma EVs that was absent in the HPA-derived EVs. Then, we evaluated the relationship between SRPX protein expression and tumor grade using immunohistochemical staining (IHC) and performed colony formation and viability assays to analyze the possible function of SRPX in glioblastoma. SRPX mRNA and protein expression were associated with tumor grade. Moreover, temozolomide (TMZ)-resistant tumor tissues showed highly positive SRPX staining, compared to all other tumor grades. Additionally, glioblastoma cells displayed enhanced SRPX gene expression when exposed to TMZ. Knockdown of SRPX gene expression via siRNA inhibited cell viability. Taken together, the results of this study suggest that SRPX can be used as a novel tumor marker for diagnostic and prognostic purposes and can also be a therapeutic target for glioblastomas. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.